Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (421-430 of 446) with videos related to

Pageof 45
Sort By:
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Advances|May 23, 2020
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Rhett P Ketterling, et al.
Blood Cancer Journal|September 29, 2025
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomesTamer Hellou, Daniel G Packard, Suheil Albert Atallah-Yunes, et al.
Blood Cancer Journal|April 14, 2022
Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)Jacqui-Lyn Saw, M Hasib Sidiqi, Michael Ruff, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Leukemia|September 2, 2017
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trialS Ailawadhi, J R Mikhael, B R LaPlant, et al.
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Pageof 45

Showing results (421-430 of 446) with videos related to

Sort By:
Pageof 45
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Advances|May 23, 2020
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Rhett P Ketterling, et al.
Blood Cancer Journal|September 29, 2025
Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomesTamer Hellou, Daniel G Packard, Suheil Albert Atallah-Yunes, et al.
Blood Cancer Journal|April 14, 2022
Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)Jacqui-Lyn Saw, M Hasib Sidiqi, Michael Ruff, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Leukemia|September 2, 2017
Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trialS Ailawadhi, J R Mikhael, B R LaPlant, et al.
Blood Advances|April 9, 2026
Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL AmyloidosisMaximilian Johannes Steinhardt, Eli Muchtar, Taxiarchis V Kourelis, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Pageof 45